Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

April 1, 2025

Study Completion Date

April 1, 2025

Conditions

Plasmodium Falciparum Infection

Interventions

DRUG

Artesunate

Artesunate is a succinic ester of artemether.

Trial Locations (1)

Makerere University-Infectious Diseases Institute, Kampala

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT05750459 - Pharmacokinetic Study of IV Artesunate to Treat Children With Severe Malaria | Biotech Hunter | Biotech Hunter